Bharat Parenterals reported a consolidated net loss of ₹3.6 crore for Q1FY27, widening from a loss of ₹0.9 crore in the same quarter last year. Consolidated revenue from operations declined 19.2% year-on-year to ₹93.7 crore, primarily due to a high base effect created by the delivery of an opening tranche of a ₹210 crore institutional order in Q1FY26. Despite the revenue drop, the group’s gross margin expanded by approximately 1,000 basis points to 50.6%, indicating improved revenue quality even as operating expenses rose 16.5% to ₹38.9 crore, driven by pre-commercial investments at its subsidiaries.

The Board of Directors approved the unaudited financial results on August 05, 2026, pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by statutory auditors Shah Mehta & Bakshi Chartered Accountants and recommended by the Audit Committee. Management emphasized that the revenue decline reflects contract lifecycle timing rather than demand loss, with the current quarter comparing the closing tranche of the large order against its opening tranche.

Financial Performance Overview

Standalone revenue from operations fell 41.2% to ₹55.5 crore from ₹94.4 crore in Q1FY26. However, standalone EBITDA margin improved to 12.3% from 11.9% in the prior year, supported by a gross margin increase to 39.8% from 33.4%. Standalone net profit declined 63.4% to ₹3.7 crore. Finance costs decreased by 51% to ₹0.7 crore, and trade receivables reduced by 32% year-on-year to ₹118.6 crore, signaling improved working capital efficiency.

Consolidated EBITDA stood at ₹8.5 crore with a margin of 9.1%, down from ₹13.8 crore at 11.9% in Q1FY26. The decline in EBITDA was entirely attributable to increased operating expenses, which rose to ₹38.9 crore (41.5% of revenue) from ₹33.4 crore (28.8% of revenue). These costs were substantially concentrated at subsidiaries Innoxel Lifesciences and Varenyam Healthcare, which are building capacity ahead of contracted forward revenue. Non-cash depreciation charges of ₹8.7 crore further pressured consolidated profitability.

Subsidiary Performance

Innoxel Lifesciences, the group’s Contract Development and Manufacturing Operations (CDMO) arm, reported revenue of ₹21.4 crore, up 164.8% year-on-year, driven by licensing, milestone, and development income. It posted an EBITDA loss of ₹1.8 crore and a net loss of ₹10.4 crore, attributed to ₹6.3 crore in depreciation and ₹2.3 crore in finance costs against a fully invested asset base. Commercial CMO supply is expected to begin in Q2FY27, with management targeting out-licensing revenue of ₹70–90 crore for FY27.

Varenyam Healthcare, focused on domestic ethical branded formulations, saw revenue rise 52.2% to ₹25.1 crore. It achieved an EBITDA of ₹3.1 crore with a margin of 12.4% and a net profit of ₹2.8 crore, reversing losses recorded in Q4FY26. The subsidiary expanded its field force to 211 medical representatives and covers over 7,500 hospitals. Varenyam Biolifesciences remains pre-operational with minimal operating costs of ₹0.09 crore.

What the Numbers Show

The divergence between standalone profitability and consolidated losses highlights the group's transitional phase. While the core manufacturing business maintains healthy margins and improves working capital efficiency, the heavy fixed-cost burden at Innoxel Lifesciences continues to drag down group-level metrics. Notably, consolidated PAT excluding Innoxel was positive at ₹6.8 crore, underscoring that the parent company and other subsidiaries remain profitable. The order book stands at ₹171 crore, covering approximately 80–85% of the revenue required for the remaining nine months of FY27.

Corporate Actions

The Board approved the re-appointment of Mr. Hemang Shah as Executive Director for a term of five consecutive years, effective July 02, 2026, subject to shareholder approval at the AGM. The company also fixed September 19, 2026, as the date for its 33rd Annual General Meeting (AGM) to be held via Video Conferencing/other Audio-Visual means (VC/OAVM).

Bharat Parenterals Limited has re-appointed Hemang Shah as an Executive Director for a term of five consecutive years, effective from July 02, 2026 to July 01, 2031. The company name Board of Directors approved the decision on August 05, 2026, based on recommendations from the Nomination and Remuneration Committee and the Audit Committee. The appointment remains subject to approval by shareholders at the company’s ensuing Annual General Meeting.

The Board verified that Mr. Shah is not debarred from holding the office of Director by any order of the Ministry of Corporate Affairs (MCA), SEBI, or any other authority. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III and SEBI Master Circular bearing No. HO/49/14/14(7)2025-CFDP2/I/3762/2026 dated January 30, 2026.

Director Profile and Tenure

Hemang Jayendrabhai Shah brings over 30 years of experience to the role and has been associated with Bharat Parenterals Limited for more than two decades. He holds a Bachelor of Commerce degree and a Master of Social Work (MSW). The Board cited his pivotal role in the growth and development of the company as key factors in his re-appointment.

Compliance and Disclosures

The company confirmed that Mr. Shah is not related to any other Director of the company. The detailed disclosures required under the SEBI LODR Regulations have been annexed to the intimation sent to the BSE Limited. The information is also available on the company’s website at www.bplindia.in .

The re-appointment ensures continuity in leadership for the Vadodara-based pharmaceutical manufacturer, which operates under WHO-GMP certification and holds Star Export House status. Shareholders will vote on the resolution during the upcoming Annual General Meeting.